A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages
<p>Abstract</p> <p>Background</p> <p>The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin...
Saved in:
Main Authors: | Fox Sarah (Author), Gasco Alberto (Author), Fruttero Roberta (Author), Cena Clara (Author), Lazzarato Loretta (Author), Sheldrake Tara A (Author), Marcarino Paolo (Author), Turnbull Catriona M (Author), Megson Ian L (Author), Rossi Adriano G (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2008-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Signaling pathways involved in LPS induced TNFalpha production in human adipocytes
by: Festy Franck, et al.
Published: (2010) -
Pain experience in children with juvenile idiopathic arthritis on TNFalpha-inhibitors
by: Jeppesen JH, et al.
Published: (2008) -
IN VITRO RELEASE MODELING OF ASPIRIN FLOATING TABLETS USING DDSOLVER
by: Agus Siswanto, et al.
Published: (2015) -
A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity
by: Rossi Adriano G, et al.
Published: (2006) -
Monitoring the hydrolyzation of aspirin during the dissolution testing for aspirin delayed-release tablets with a fiber-optic dissolution system
by: Yan Wang, et al.
Published: (2012)